Patrick Pierre Michel is a Senior PI at the Paris Brain institute (ICM). He has authored or co-authored 129 peered reviewed publications (H index 49, Times Cited < 10,000; Orcid ID: https://orcid.org/0000-0001-5607-3119). Patrick Pierre Michel holds a doctorate in pharmacy (1985) and a PhD in neuroscience (1990) from the University Claude Bernard (Lyon 1). He pursued a scientific career oriented towards translational research in the field of neurodegenerative disorders with a particular emphasis on Parkinson’s disease (PD). He has worked previously in both academic and pharmaceutical environments. From 2011--2021, he successfully administered a cell culture core facility (>220 users) where he implemented platform activities. He has solid expertise in cellular pharmacology and has established cell culture models for investigating the mechanisms of neurodegeneration and neuroinflammation. Some of these models are currently used for screening purposes. A number of research projects have led to follow-up studies in animal (C elegans, rodent) models of PD or related disorders. He has also recently contributed to physiopathological studies in patients. He is the inventor of several patents and has been involved in a number of projects with biotech companies and industry partners.
Patrick Pierre Michel is a Senior PI at the Paris Brain institute (ICM). He has authored or co-authored 129 peered reviewed publications (H index 49, Times Cited < 10,000; Orcid ID: https://orcid.org/0000-0001-5607-3119). Patrick Pierre Michel holds a doctorate in pharmacy (1985) and a PhD in neuroscience (1990) from the University Claude Bernard (Lyon 1). He pursued a scientific career oriented towards translational research in the field of neurodegenerative disorders with a particular emphasis on Parkinson’s disease (PD). He has worked previously in both academic and pharmaceutical environments. From 2011--2021, he successfully administered a cell culture core facility (>220 users) where he implemented platform activities. He has solid expertise in cellular pharmacology and has established cell culture models for investigating the mechanisms of neurodegeneration and neuroinflammation. Some of these models are currently used for screening purposes. A number of research projects have led to follow-up studies in animal (C elegans, rodent) models of PD or related disorders. He has also recently contributed to physiopathological studies in patients. He is the inventor of several patents and has been involved in a number of projects with biotech companies and industry partners.